J M R Van der Meer, R J A Maas, K Guldevall, K Klarenaar, P K J D De Jonge, J S Hoogstad-van Evert, A B van der Waart, J Cany, J T Safrit, J H Lee, E Wagena, P Friedl, B Önfelt, L F Massuger, N P M Schaap, J H Jansen, W Hobo, H Dolstra
{"title":"修正:IL - 15超级激动剂N - 803通过CD34+祖细胞衍生的NK细胞改善IFNγ的产生和白血病和卵巢癌细胞的杀伤。","authors":"J M R Van der Meer, R J A Maas, K Guldevall, K Klarenaar, P K J D De Jonge, J S Hoogstad-van Evert, A B van der Waart, J Cany, J T Safrit, J H Lee, E Wagena, P Friedl, B Önfelt, L F Massuger, N P M Schaap, J H Jansen, W Hobo, H Dolstra","doi":"10.1007/s00262-021-03049-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"3367"},"PeriodicalIF":5.1000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505330/pdf/","citationCount":"1","resultStr":"{\"title\":\"Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.\",\"authors\":\"J M R Van der Meer, R J A Maas, K Guldevall, K Klarenaar, P K J D De Jonge, J S Hoogstad-van Evert, A B van der Waart, J Cany, J T Safrit, J H Lee, E Wagena, P Friedl, B Önfelt, L F Massuger, N P M Schaap, J H Jansen, W Hobo, H Dolstra\",\"doi\":\"10.1007/s00262-021-03049-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":520581,\"journal\":{\"name\":\"Cancer immunology, immunotherapy : CII\",\"volume\":\" \",\"pages\":\"3367\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505330/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer immunology, immunotherapy : CII\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00262-021-03049-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology, immunotherapy : CII","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00262-021-03049-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.